Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

Clinical Pharmacology in Drug Development

Volumn 4, Issue 3, 2015, Pages 226-236

  Devineni, Damayanthi ^a   Manitpisitkul, Prasarn ^a   Murphy, Joseph ^a   Skee, Donna ^a   Wajs, Ewa ^b   Mamidi, Rao N V S ^a   Tian, Hong ^a   Vandebosch, An ^b   Wang, Shean Sheng ^a   Verhaeghe, Tom ^b   Stieltjes, Hans ^b   Usiskin, Keith ^a  

^a LLC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Glyburide; Metformin; Pharmacokinetics; Simvastatin; Type 2 diabetes mellitus

Indexed keywords

3 HYDROXYGLYBURIDE; 4 HYDROXYGLYBURIDE; CANAGLIFLOZIN; DRUG METABOLITE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METFORMIN; SIMVASTATIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RASH; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ARGENTINA; BIOAVAILABILITY; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; ARGENTINA; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CANAGLIFLOZIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GLYBURIDE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; SIMVASTATIN; UNITED STATES; YOUNG ADULT;

EID: 84929576870     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.166     Document Type: Article

References (30)

1. National Diabetes Statistics. 2011; National Diabetes Information Clearinghouse (NDIC) Last updated on September 09, 2013. http://diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed on December 18, 2013.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-1379.
3. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 1995; 2013; 41:72-84.
4. Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of Hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014; 36:698-710.
5. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35:1232-1238.
6. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53:601-610.
7. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010; 70:377-385.
8. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15:372-382.
9. Rao N, Chou T, Ventura D, Abramowitz W. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther. 2005; 27:1596-1606.
10. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009; 85:78-85.
11. Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011; 55:3091-3098.
12. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis. 2010; 9:144.
13. Nishio S, Watanabe H, Kosuge K, et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005; 28:223-227.
14. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1 B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011; 63:157-181.
15. WHO. World Health Organization: Diabetes-Fact sheet N°312 Reviewed October 2013. http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed on May 29, 2014.
16. Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009; 85:607-614.
17. Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008; 66:36-42.
18. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012; 14:539-545.
19. Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996; 36:1012-1021.
20. Vishwanathan K, Mair S, Gupta A, et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. Drug Metab Dispos. 2014; 42:932-942.
21. He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin. 2009; 25:1265-1272.
22. Polli JW, Humphrey JE, Harmon KA, et al. Assessment of remogliflozin etabonate, a sodium-dependent glucose co-transporter-2 inhibitor, as a perpetrator of clinical drug interactions: a study on drug transporters and metabolic enzymes. J Diabetes Metab. 2012; 3:200.
23. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013; 52:815-831.
24. Fallah A, Deep M, Smallwood D, Hughes P. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas Med J. 2013; 6:112-114.
25. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41:343-370.
26. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012; 29:163-177.
27. Macha S, Lang B, Pinetti S, Woerle HJ, Broedl UC. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers [abstract no. PCS-33-7]. J Diabetes Investig. 2012; 3:228.
28. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382:941-950.
29. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36:2508-2515.
30. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013; 67:1267-1282.